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Abstract
Background: Cervical cancer is the greatest cause of age-weighted years of life lost in the developing world.
Human papillomavirus (HPV) infection is associated with a high proportion of cervical cancers, and HPV vaccination
may help to reduce the incidence of cancer. The aim of the study was to identify barriers, obstacles, and strategies and
to analyze key concerns and lessons learned with respect to the implementation of HPV vaccination program in
low- and middle-income countries.
Methods: The Gardasil Access Program (GAP) is a donation program established to enable organizations and
institutions in eligible low-resource countries to gain operational experience designing and implementing HPV
vaccination programs. This study used an online survey to capture the experiences and insights of program managers
participating in the GAP. Different factors related to HPV vaccination program management were collected. A
mixed-method approach enabled the presentation of both quantitative measurements and qualitative insights.
Results: Twenty-nine programs implemented by 23 institutions in 19 low- and middle-income countries were
included. Twenty programs managers (97.7 %) reported that their institution implemented sensitization strategies
about vaccination prior to the launch of vaccination campaign. The most frequently reported obstacles to HPV
vaccination by the program managers were erroneous perceptions of population related to the vaccine’s safety
and efficacy. Reaching and maintaining follow-up with target populations were identified as challenges. Insufficient
infrastructure and human resources financing and the vaccine delivery method were identified as significant health
system barriers. Coupling HPV vaccination with other health interventions for mothers of targeted girls helped to
increase vaccination and cervical cancer screening. The majority of program managers reported that their programs
had a positive impact on national HPV vaccination policy. The majority of institutions had national and international
partners that provided support for human resources, technical assistance, and training and financial support for health
professionals.
Conclusion: Local organizations and institutions can implement successful HPV vaccination campaigns. Adequate and
adapted planning and resources that support information sharing, sensitization, and mobilization are essential for such
success. These results can inform the development of programs and policies related to HPV vaccination in low- and
middle-income countries.
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Background
Cervical cancer, the third most common cause of cancer
in women around the world, is a significant global health
challenge, and is the greatest cause of age-weighted years
of life lost in the developing world due to its high inci-
dence [1–3]. Cervical cancer is the second major cause
of cancer-related deaths among women in low and
middle-income countries (LMICs) [4, 5]. Human Papil-
loma Virus (HPV) infection is the most common sexu-
ally transmitted infection (STI), with a global prevalence
of 12 % of women [3, 6, 7]. Two HPV serotypes, HPV-
16 and HPV-18, are found in nearly 70 % of high-grade
cervical cancers [2, 8]. Approximately 291 million
women worldwide are estimated to have human papillo-
mavirus (HPV) infection of the cervix [6, 7] and the
prevalence is higher in women younger than 25 years of
age (16.9 %) [2, 9].
Since 2006, two prophylactic HPV vaccines have been
available, and each has shown 90 % efficacy in prevent-
ing HPV type 16- and 18-associated high-grade cervical
lesions [10–12]. While both vaccines are being deployed
in developed countries, their use in LMICs has been lim-
ited due to cost and a variety of other factors [13, 14].
Recognizing that these factors were impeding the broad
use of HPV vaccination in LMICs, Merck & Co., Inc.
pledged to donate Gardasil® [Human Papillomavirus
Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recom-
binant] to eligible LMICs through the Gardasil Access
Program (GAP). Axios Healthcare Development is the
recipient of this donation and is responsible for man-
aging the GAP. The program was established to enable
organizations and institutions in eligible LMICs to gain
operational experience designing and implementing
HPV vaccination programs, with the goal of supporting
the development of successful child and adolescent
immunization models [15, 16].
Concerns about the limited use of HPV vaccine in
LMICs led to the implementation of a variety of HPV
vaccine demonstration projects designed to generate evi-
dence about effective ways to reach young adolescent
girls [15, 16]. While these demonstration programs have
provided important insights into factors that impact the
uptake of HPV vaccine in specific countries and commu-
nities, the lessons learned may also be relevant to the
implementation of HPV vaccination campaigns in
general [17, 18].
Despite the proven safety, efficacy and cost-effectiveness
of HPV vaccine, there remain a number of unidentified is-
sues that impede its routine use in LMICs. While a num-
ber of HPV vaccination pilot programs have been
undertaken in lowest-income countries, published results
from these programs do not typically include information
related to program management. As more countries con-
sider introducing HPV vaccine, a review of the lessons
learned from vaccination programs conducted in LMICs
was undertaken in order to identify barriers and difficul-
ties to implementation and sustainability of HPV vaccin-
ation programs [17–19]. The experiences of programs
participating in the GAP provide additional opportunities
to further document and understand the factors related to
launching new vaccination interventions in LMICs.
Review of the lessons learned from pilot programs
undertaken in LMICs is essential for advancing our
knowledge of barriers and solutions to implementing
sustainable HPV vaccine programs. The aim of this
study was to identify barriers, obstacles, and strategies
and to analyze key concerns and lessons learned with re-
spect to the implementation of HPV vaccination in insti-
tutions that managed HPV vaccination programs in
LMICs through the GAP.
Methods
Donations through the Gardasil Access Program were
available to interested government Ministries of Health
(MoH) and national and international non-governmental
organizations (NGOs), with the approval of national
health authorities. Axios Healthcare Development has
been responsible for managing, monitoring, and distrib-
uting HPV vaccine for the GAP.
Organizations and institutions participating in the
GAP are responsible for covering all other costs associ-
ated with their vaccination campaigns, including import-
ation, storage, cold chain management, distribution of
vaccine, data collection, and management of the vaccin-
ation campaigns. Program managers were independent
from Axios and were employees of the organization at
which they helped to manage the GAP. The GAP en-
courages participating organizations to adhere to WHO
guidelines for HPV vaccination, which recommends a
target age range of 9 or 10 years of age through 13 years
of age [20]. The vaccination programs used three models
for vaccine delivery: school-based models administered
vaccine at local school facilities; health facility-based
models administered vaccine at health facilities, hospi-
tals, and mobile clinics; and mixed models used both
schools and clinics to deliver vaccine [15, 16]. This study
was conducted at the end of the vaccination programs
and used a mixed-method approach to provide a de-
scriptive impact evaluation from the perspective of par-
ticipating GAP institutions. This approach enables the
presentation of both quantitative measurements and
qualitative insights.
A key method approach of this study was to develop
an online survey that could be used to capture the expe-
riences and insights of program managers. The first step
in developing this survey was identifying the types of in-
formation to be collected. Two health professionals from
Axios Healthcare Development (MHB, MR) made in-
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country site visits to 10 institutions representing 15 pro-
grams in 6 countries (Table 1). To ensure representation
of countries in Latin America, Asia, and Africa, the pro-
grams were randomized and then stratified by continent
(Table 1). Structured qualitative interviews were con-
ducted with the program managers, and a variety of rele-
vant topics were explored regarding recruitment,
implementation, follow-up, and management of the vac-
cination programs. The aim was to develop a question-
naire capable of accurately assessing the key challenges
related to the implementation of an HPV vaccination
program. During the first step of the study, face-to-face
interviews were conducted with the program managers
in the different sites. The semi-structured interview ap-
proach was believed to be the most informative and ap-
propriate for high-level participants, as opposed to a
highly- structured questionnaire. This format facilitated
the free expression of opinions and ideas among pro-
grams managers, and allowed for probing and clarifica-
tion of responses, and for the identification of new
issues and topics relevant in the implementation of an
HPV-vaccination program.
The results of these interviews were used to develop
the final questionnaire, which was administered online
to the program managers of the institutions included in
the GAP that completed at least vaccination of the first
targeted cohort. The GAP managers at these institutions
received a link by email to complete the online standard-
ized questionnaire, which included structured, closed
questions, and open-ended questions, in English,
Spanish, and French.
Factors related to program management were assessed
in the following areas: vaccination sensitization strategies
and obstacles reported by parents, identification of ob-
stacles to follow up and strategies to reach girls lost to
follow-up, and difficulties related to supply chain man-
agement and data management. The number and type of
national and international partners that supported the
vaccination programs were also collected with respect to
technical assistance, logistics, human resources and their
training, financial support, and in-kind donations.
Statistical analyses were descriptive, with variables
expressed in percentages. Verbatim and qualitative data
were collected during the site visits to the 10 institu-
tions, and open-ended questions were included in the
final online questionnaire. Qualitative data were system-
atically analyzed. A directed content analysis approach
was used to analyze the data and to identify the key
themes. Two authors (JL, MHB) reviewed all qualitative
comments extracted from the questionnaires and placed
them into broader categories based on content and the-
matic saturation. Illustrative quotes have been included
in this report along with information about the role that
each survey participant played in the vaccination pro-
gram. Key findings and quotes were compiled in a
Microsoft Excel table and coded according to topic or
theme. Responses were reported if at least two people
gave a similar response. Final decisions on comments
categories were discussed with a third author (EA).
Results
A total of 29 programs implemented by 23 institutions
in 19 countries are included in this study (Table 1); one
program manager (in one institution) has not responded
to the survey. In Bolivia, two different institutions im-
plemented four programs; in Honduras, four different
institutions managed four programs; in Nepal, one in-
stitution managed three programs, and in Cambodia
and Lesotho one institution managed two programs in
each country (Table 1). Fourteen institutions (60.9 %)
were national health institutions of the MoH and nine
institutions were international or national NGOs. As
specified in the Methods section, 10 institutions in six
countries were previously visited as part of the final
survey development effort (Table 1). Regarding vaccin-
ation delivery models, 18 programs were school-based
models, five were health facility-based models, and six
were mixed models.
Table 1 Countries and number of institutions and programs
included in the Gardasil Access Program 2009-2014






Bhutan 1 1 0
Bolivia 2 4 2
Cambodia 1 2 1
Cameroon 1 1 1
Georgia 1 1 0
Ghana 1 1 0
Guyana 1 1 0
Haiti 1 1 0
Honduras 4 4 4
Kenya 1 1 0
Kiribati 1 1 0
Lesotho 1 2 1
Mali 1 1 0
Moldova 1 1 0
Nepal 1 3 1
Tanzania 1 1 0
Uganda 1 1 0
Uzbekistan 1 1 0
Zambia 1 1 0
Total 23 29 10
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Sensitization strategies for HPV vaccination
Twenty-two program managers (95.7 %) reported that
their institution implemented at least one sensitization
strategy about the vaccination program prior to the
launch of the campaign; all of the 22 institutions
responding implemented sensitization meetings in the
communities and organize meetings with the girls
(Table 2). The most commonly reported challenges re-
lated to vaccination sensitization were misinformation
(52.2 %) and a lack of understanding of information
(26.1 %) about HPV vaccination.
Identified obstacles
Nineteen program managers (82.6 %) reported that par-
ents had objections to the HPV vaccine, the most com-
mon of which were the misconceptions that HPV
vaccination is a method for sterilizing girls (Table 2).
Program managers underlined the importance of provid-
ing effective messages to parents: “It is important to
have good one-on-one education with parents to over-
come misinformation.” The integration of the HPV vac-
cine into the Expanded Program of Immunization (EPI)
was also found to be an effective message: “In general
parents were open to the HPV vaccine because children
received routine immunizations - this helped with accept-
ance of Gardasil because it was integrated within EPI”.
The most frequently reported misinformation was re-
lated to the reproductive health of girls receiving HPV
vaccination, as specified by two program managers:
“Another myth that we had to fight against was that the
vaccine was seen as ‘authorization to have sexual rela-
tions’”. Information strategies designed to address these
misperceptions remained a crucial point for the pro-
grams managers: “In rural areas we encountered more
lack of information, while in urban areas it was more
about misinformation”; “Understanding myths and
knowledge gaps within the communities provided us with
the right information to create appropriate messages for
education”; “The best strategy is to work directly with
parents and provide information directly to girls.”
A total of 21 institutions (91.3 %) required informed
consent, including written informed consent (17 insti-
tutions, 81.0 %), oral informed consent (2, 9.5 %), and
informed consent for the parents to refuse vaccination
(2, 9.5 %). Three program managers highlighted socio-
cultural barriers related to the utilization of informed
consent: “Asking for written consent was taken as a
negative sign by parents who became suspicious”; “The
best strategy is to work directly with parents, especially
for explaining the process and getting consent and mak-
ing sure they understood the process”; “Providing vac-
cines free of charge led to parents being more suspicious
and less concerned about girls returning for the subse-
quent doses.”
Follow-up strategies
All the institutions were challenged with girls lost to
follow-up during the vaccination campaigns. The most
frequent obstacles to follow-up were girls changing
schools or moving away, and school vacation or examin-
ation. One third of the institutions also reported logis-
tical obstacles to follow-up, such as challenges with
transportation, and the availability of human and finan-
cial resources needed to bring girls to vaccination sites
(Table 2). Reaching adolescent girls to deliver vaccines
was also reported as a significant challenge, and individ-
ual programs used a variety of strategies to address this
obstacle. The most frequent strategies were to contact
teachers and school administration, and phone calls to
girls or her family members. Multiple institutions also
used the support of contacts in their communities
(Table 2): “The staff implemented an innovative method
of ‘peer tracking’ of girls who needed second and third
doses in small communities, some of which did not have
cell phone coverage”; “Once the team found one girl who
needed a second or third dose, they would ask her to help
them locate other girls who needed second or third
doses”; “The process of follow up was costly in terms of
time, finances, and human resources”.
Management of supply chain and data monitoring
systems
Because most of the institutions participating in the
GAP have a history of experience delivering other vac-
cines that are included in the national immunization
program or the EPI, management of vaccine supply
chain did not pose new challenges, and 43.5 % of pro-
gram managers reported no difficulties with this aspect
of their vaccine campaigns: “Logistics and cold chain
management was apparently not a challenge or issue for
any of the projects, apart from some isolated and unex-
pected events”; “Providing supplies and the vaccines in
advance (around five days) guarantees the success of the
vaccination campaign”; “The main challenge appears to
be with the storage capacity at some health facilities.”
However, it should be noted that 13 institutions (56.5 %)
did report difficulties with HPV vaccine supply chain
management, including expiration of vaccine date
(46.2 %) and difficulties transporting vaccine to adminis-
tration sites (38.5 %) (Table 2).
Data management and monitoring and evaluation sys-
tems were also investigated. Only one institution aggre-
gated the data rather than collecting individual data for
each girl vaccinated. Individual data were recorded in a
registry and on individual records in 17 institutions
(77.3 %). Of those institutions with individual records,
seven (31.8 %) recorded the data in an electronic database.
Overall, 82.6 % of institutions managed their programs
electronically. Sixteen institutions reported difficulties with
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the data management of vaccination programs, with late or
incomplete vaccination reports listed as two of the most
common challenges (Table 2).
Interventions coupled with HPV vaccination
A total of 13 institutions (56.5 %) coupled HPV vaccin-
ation with other health interventions for mothers of tar-
geted girls, including screening of cervical cancer in 12
institutions, tetanus vaccination in one institution, and
both cervical cancer screening and tetanus vaccination
in one institution. The program managers found this ap-
proach to be effective: “Some of the women participating
in these campaigns had their girls vaccinated for HPV,
and some of the mothers of the girls who received vacci-
nations at school ended up receiving screening for cer-
vical cancer”; “The mother-daughter approach was
effective in reaching out-of-school girls in rural areas.”
Lessons learned and impact on public health system
Sixteen institutions (69.6 %) reported that their pro-
grams had a positive impact on national HPV vaccin-
ation policy: “The program confirmed that the vaccine
was highly acceptable; HPV vaccination was built into
the national cervical cancer control strategy”; “The most
important result of implementing GAP projects in our
country is that we now have the experience of imple-
menting HPV vaccination projects”; “The country
Table 2 Strategies used, obstacles, and difficulties reported by
the institutions, Gardasil Access Program 2009-2014 (N = 23)
Number Percent
Vaccination sensitization strategies
No sensitization conducted 1 4.3
At least one sensitization conducted 22 95.7
Sensitizations conducted
Meetings in the communities 22 100
Meetings with girls to be vaccinated 22 100
Media campaigns (radio, TV, newspapers) 17 77.2
Meetings with mothers at time of cervical
cancer screening
13 59.1
Obstacles for vaccination reported by the parents
No obstacle reported 4 17.4
At least one obstacle reported 19 82.6
Obstacles reported
Vaccination is a way to sterilize the girls 11 57.9
Vaccine is not safe 8 42.1
Vaccination only for girls and not for boys 7 36.8
Vaccination is a family planning medication 5 26.3
Girls aged 9 years are too young to receive
vaccination
5 26.3
Vaccination is not effective in preventing HPV
infection and cervical cancer
4 21.1
Vaccination gives girls permission to have sex 3 15.8
Strategies to reach girls lost to follow-up
No strategy implemented 0 0
At least one strategy implemented 23 100
Strategies implemented
Teachers and school administration contact 17 73.9
Phone calls to girls or family 15 65.2
Community leader contact 13 56.5
Visit to girl at home 8 34.8
Religious leader contact 2 8.7
Girls’ peers 2 8.7
Obstacles for girls’ follow-up
No challenge reported 3 13.0
At least one obstacle reported 20 87.0
Obstacles reported
Girls have changed schools or move away 16 80.0
School vacation or examination 11 55.0
Incorrect reporting or lack of details on identity 8 40.0
Limited transportation vehicles available 7 35.0
Limited financial resources available 7 35.0
Limited human resources available 5 25.0
Table 2 Strategies used, obstacles, and difficulties reported by
the institutions, Gardasil Access Program 2009-2014 (N = 23)
(Continued)
Difficulties of supply chain management
No difficulty reported 10 43.5
At least one difficulty reported 13 56.5
Difficulties reported
Vaccines reached expiration date 6 46.2
Difficulties in transporting unused vaccines
from sites
5 38.5
Projections of vaccine needed on site did
not match number of girls in the field
3 23.1
Insufficient storage capacity at site level 1 7.7
Vaccines damaged during transportation to site 1 7.7
Difficulty of data management
No difficulty reported 7 30.4
At least one difficulty reported 16 69.6
Difficulties reported
Reports from vaccination sites were not
received in time
14 87.5
Reports from vaccination sites were incomplete
or incorrect
7 43.8
The system in place was time-intensive and
cumbersome
3 18.8
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benefited from the program: we are now approaching cer-
vical cancer in a comprehensive way, and the GAP led to
the establishment of cervical cancer screening centers”;
“We had to include Gardasil vaccine issues in the Sexual
Reproductive Policy and National Adolescent Health
Policy.”
A positive impact on health policy for cervical cancer
screening was also reported: “After the GAP project, cer-
vical cancer screening projects started in our country”;
“Not exactly a change in national policy, but the
National Commission on Immunization Program has
recommended undertaking a study on HPV Vaccination
activities. The findings from the GAP program will help
to inform decision-making related to the vaccination pro-
gram”; “The start of HPV projects put the issue of cer-
vical cancer on the table for discussion. Because of these
discussions and significant political pressure from differ-
ent groups, a National Prevention Plan against Cervical
Cancer was created in the years following the GAP pro-
ject. This plan included the use of HPV vaccination as
an important strategy for cervical cancer management.”
At the end of the GAP, ten institutions applied for GAVI
Vaccine Alliance Program funding: “The MoH used our
experience to apply for GAVI funding.”
Five institutions (21.7 %) also reported a direct impact
on cervical cancer awareness: “The level of knowledge re-
lated to cervical cancer has increased, in particular in
those populations where the vaccination took place”; “It
has increased the number of women that do their PAP
smears.”
Table 3 presents the number and type of national and
international partners that supported the HPV vaccin-
ation programs. The most frequent support areas were
for human resources (21 institutions; 91.3 %), technical
assistance (19; 82.6 %) and training for health profes-
sionals and financial supports (18; 78.3 %). Regarding
the partners that supported the programs, national Ex-
panded Programs for Immunization were frequently in-
volved in technical assistance, human resources, and
training; MoH supported technical assistance and logis-
tics; and Ministries of Education were primarily involved
in human resources. International NGOs supported
eight institutions (44.4 %).
Discussion
This study of 23 key programs managers who were ac-
tively involved in the implementation of a variety of
HPV programs combines qualitative and quantitative
research on the challenges and opportunities associ-
ated with implementing the HPV vaccine in LMICs.
Our findings document the experiences of various
strategies and approaches related to HPV vaccination
implementation in LMICs and provide lessons learned
and best practices that may be applied to the
implementation of other HPV vaccine programs. The
most frequently reported obstacles to HPV vaccination
were erroneous perceptions that the GAP was using
HPV vaccine in the context of a clinical trial, that the
HPV vaccine was unsafe, and that the vaccine was be-
ing used to sterilize young girls. These misperceptions
among parents [20], in concert with rumors and socio-
cultural barriers, underscore the need for effective and
accurate communication about the vaccine’s prevent-
ive health benefits, as well as appropriate sensitization
and advocacy building among parents and key com-
munity stakeholders [21–26]. Education related to
HPV as an STI and as a primary cause of cervical
cancer is important for mitigating these sociocultural
issues [17]. Previously, we demonstrated that the
inclusion of key messages regarding the safety and
efficacy of the vaccine had a positive impact on
vaccination coverage. Key sensitization messages that
address safety and efficacy at the launch of a vaccine
campaign may help to increase acceptance of HPV
vaccination [16].
Reaching and maintaining follow-up with adolescent
girls in order to deliver HPV vaccines were challenges
for program managers. While vaccination programs
have traditionally focused on children less than five
years of age, a vaccination such as HPV, which is tar-
geted to adolescents, requires different mobilization
and delivery infrastructure. There is currently no ex-
perience in mass vaccination in adolescent populations,
which may explain the reported challenges. Contacts
with schoolteachers and administrators were frequently
used as a strategy to reach girls lost to follow-up in the
18 programs that utilized school-based delivery models.
School-based projects faced additional challenges when
vaccination dates occurred outside of scheduled school
days, and it was exponentially more difficult to prevent
loss to follow-up in these instances. Despite these chal-
lenges, school-based vaccination delivery methods were
most effective at reaching girls within the WHO-
recommended age range, which is likely due to the fact
that girls aged 9-13 years are not usual “clients” of the
health care system [27–29]. Of the three types of
vaccine delivery models assessed in this study, the
school-based model was found to be the strongest
positive predictive factor of higher vaccine coverage
[14, 16]. One study found that school-based models
have also been effective in demonstration programs in
Peru, Uganda, Vietnam, and India (vaccine coverage
ranged from 82.6 % to 96.1 %) [30]. School absenteeism
was one primary difficulty reported by the program
managers, suggesting that school-based delivery models
are appropriate, but require adequate methods to cap-
ture and follow girls who are absent the day of vaccin-
ation or who moved away [17, 31].
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Table 3 Number and type of national and international
partners supporting HPV vaccination programs, Gardasil Access
Program 2009-2014 (N = 23)
Type of supports and partners Number Percent
Technical assistance




≥ 3 7 30.4
Partners involved
Expanded Program on Immunization 11 57.9
International NGOs 4 21.1
Ministry of Education 2 10.5
Ministry of Health 10 52.6
National NGOs 6 31.6
Other United Nation Agencies 1 5.3
World Health Organisation 3 15.8
Logistics




≥ 3 7 30.4
Partners involved
Expanded Program on Immunization 2 12.5
International NGOs 6 37.5
Ministry of Education 1 6.3
Ministry of Health 8 50.0
National NGOs 4 17.4
Other United Nation Agencies 0 0
World Health Organisation 3 81.3
Human resources




≥ 3 10 43.5
Partners involved
Expanded Program on Immunization 9 42.9
International NGOs 5 23.8
Ministry of Education 10 47.6
Ministry of Health 2 9.5
National NGOs 9 42.9
Other United Nation Agencies 1 4.8
World Health Organisation 0 0
Table 3 Number and type of national and international
partners supporting HPV vaccination programs, Gardasil Access
Program 2009-2014 (N = 23) (Continued)
Training of human resources




≥ 3 6 26.1
Partners involved
Expanded Program on Immunization 9 50.0
International NGOs 5 27.8
Ministry of Education 1 5.6
Ministry of Health 6 33.3
National NGOs 4 22.2
Other United Nation Agencies 0 0
World Health Organisation 3 16.7
Financial support




≥ 3 4 17.4
Partners involved
Expanded Program on Immunization 2 11.1
International NGOs 8 44.4
Ministry of Education 0 0
Ministry of Health 6 33.3
National NGOs 5 27.8
Other United Nation Agencies 2 11.1
World Health Organisation 1 5.6
In-kind donation




≥ 3 4 17.4
Partners involved
Expanded Program on Immunization 2 15.4
International NGOs 5 38.5
Ministry of Education 3 23.1
Ministry of Health 2 15.4
National NGOs 4 30.8
Other United Nation Agencies 0 0
World Health Organisation 1 7.7
Ladner et al. BMC Health Services Research  (2016) 16:575 Page 7 of 10
Community involvement actions appeared to impact
the programs with respect to both sensitization strat-
egies before launch of the HPV vaccination campaign as
well as reaching girls lost of follow-up once the cam-
paign was underway [16, 24, 26]. The program managers
recognized that it was important for key stakeholders to
understand, accept, and approve of the benefits associ-
ated with HPV vaccination. Understanding which as-
pects of an HPV vaccine campaign are most influenced
by community standards, morals, and expectations may
help in developing community engagement actions that
impact coverage and adherence to vaccination [16].
Community sensitization about the availability and value
of vaccinating school-aged girls against HPV may impact
vaccine uptake. A study in Brazil found that the initial
method used to notify parents about the vaccine had a
significant impact on vaccine indicators [28].
Insufficient infrastructure and human resources finan-
cing and the delivery method were identified as signifi-
cant health system barriers: assistance programs helped
to address these factors and support national and inter-
national vaccine programs [17–19]. National or inter-
national partners supported all the GAP programs
included in this study. Given the high proportion of pro-
grams in our study sample that used school-based deliv-
ery models, Ministries of Education played an important
role in supporting the availability of human resources.
The most frequent partners were national (MoH and
EPI). Eighteen programs were financially supported by
and had significant involvement with international
NGOs. Our findings suggest that successful implementa-
tion of HPV vaccination programs may be feasible in
low-resource settings, provided that the health system
structure for immunization and national and inter-
national financing options are well understood. Delivery
strategies built on the strengths of existing national EPI
programs that have strong partnerships across multiple
healthcare delivery sectors may also enable successful
HPV vaccination programs in low-resource settings.
Programs such as the GAP were established to donate
limited amounts of the vaccine to countries for demon-
stration programs designed to test HPV vaccine delivery
strategies [15, 16]. Such pilot programs suggest that in-
country ownership and development capacity may con-
tribute to the long-term success and sustainability of
vaccine delivery [16, 17].
The data reported here provide lessons for develop-
ment of public health programs and policies as countries
go forward in national decision-making related to HPV
vaccination. These results suggest that local organiza-
tions and institutions can implement successful HPV
vaccination campaigns. Our results also demonstrate
that private initiatives to increase access to novel health
interventions can have a significant impact on public
health issues and foster diverse partnerships among gov-
ernment agencies, NGOs, and private organizations. The
diverse HPV vaccine programs included in this study pro-
vide concrete examples of how such programs can be
adapted to address local and regional issues and concerns,
and provide a useful framework in which countries can
consider how best to expand their own HPV vaccination
programs based on their individual epidemiological, eco-
nomic, and health system challenges [22].
The results of HPV vaccine experiences so far in
LMICs are encouraging, and the continued sharing of
outcomes data, successes, and challenges is critical to
the reproducibility of successful HPV vaccine interven-
tions. Considerable progress has been made in several
LMICs and it is important to identify and understand
those factors that are transferable to other settings.
Demonstration and pilot projects in several LMICs have
shown that a variety of delivery methods, including the
use of schools, special campaigns, health centers or
combined strategies, can reach a large proportion of eli-
gible girls, and that advocacy and sensitization are essen-
tial elements for success [17, 19, 32].
While our results provide practical information about
programs for HPV vaccine introduction in low and
middle-resource settings, there are some limitations to
be noted. A key limitation of this study is that it repre-
sents the experiences and opinions of the program man-
agers of the GAP rather than all the HPV vaccination
programs in LMICs. Similarly, there are inherent limita-
tions associated with data that are self-reported rather
than obtained through objective assessment or observa-
tion. However, the design of our study, which utilized
both qualitative and quantitative data collection, and uti-
lized a final study questionnaire that was developed fol-
lowing 10 site visits in six countries and was designed to
address potential issues related to self-reported data,
should help to limit the bias associated with self-
reporting. This study is also limited by the design
approach, which measured the impact of the GAP in dif-
ferent areas at the program’s end. This approach does
not allow us to conduct analyses on a program-by-
program or country-by-country basis, or to compare the
quality or type of HPV vaccination programs or other
type of vaccine delivery provided before and after imple-
mentation of the GAP, which could provide additional
validation of the program’s impact on these services.
However, with the goal of developing a highly inform-
ative online survey, we investigated and developed our
questionnaire based on site visits, which provides some
level of corroboration between reported and observed
results. The results of the survey utilized in this study
appear to be robust and do provide important insight
into the impact of a donation program on a variety of
services and health activities at the local, institutional,
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and national levels. While the current study does not
focus on vaccine delivery models, we previously reported
that school and health clinic-based models appeared as
predictive factors for vaccination coverage and that HPV
vaccine campaigns tailored to meet the needs of com-
munities can be effective [15, 16]. The implementation
of the GAP appears to have triggered changes at the
national level that may have long-term positive effects.
For LMICs, it is a challenge to accelerate HPV vaccin-
ation programs and also to conduct impact analyses
around such programs. Considerable progress has been
made in several LMICs and it is important to identify
and understand lessons that may be transferable to other
settings worldwide [17, 18]. School-based programs have
been successful [15, 28, 29, 32], but innovative imple-
mentation approaches will be necessary to reach broader
populations. The suspension of a demonstration HPV-
vaccination program, in India following opposition and
activism within the community underscores the import-
ance of ensuring that new research approaches engage
with the members of the community in which they are
undertaken and incorporate societal concerns, public
emotions, and local politics. This type of engagement is
essential to understand and address the societal chal-
lenges of implementing HPV vaccination programs [33].
Developing new alternatives that expand access to HPV
and cervical cancer prevention resources will require in-
put from multiple stakeholders, including governments,
NGOs, the scientific community, drugs companies, and
communities [33]. More research is needed on several
practical issues, such as how to increase access to HPV
vaccines and to develop the implementation of HPV vac-
cination programs in LMICs. This study could provide
insight into strategies that could be used to determine
best practices related to sensitization strategies, stigma
avoidance, engaging with the community, and follow-up
with young girls during the vaccination campaign in par-
ticular socio-cultural contexts.
Conclusion
Routine vaccination in adolescents remains challenging.
The data reported here from programs focused on vaccin-
ating adolescent girls provides lessons that may be applied
to the development of public health programs and policies
as countries go forward in national decision-making for
HPV vaccination. Our findings in a large sample of HPV
vaccination programs demonstrate that continued sharing
of evidence, successes, and challenges is critical to the suc-
cessful scale-up of HPV vaccine interventions worldwide.
These findings underscore the need for adequate and
adapted planning and resources that support information
sharing, sensitization, and mobilization. The GAP provides
a model for how private initiatives can have a significant
impact on public health issues.
The diverse HPV vaccine programs included in this
study provide concrete examples of how such programs
can be adapted to address local and regional issues and
concerns, and provide a useful framework in which
countries can consider how to best expand their own
HPV vaccination programs based on their individual epi-
demiological, economic, and health system challenges.
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